RxDoctor Payments Data

Muhammad Kang, DO

Cardiovascular Disease · Okemos, MINPI 1205100070

Payments from drug & device makers

$4,570in general payments, 2019–2025

Across 220 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$971
  • Amgen$616
  • Pfizer$376
  • Boehringer Ingelheim$324
  • Johnson & Johnson$304
  • E.r. Squibb & Sons, L.L.C.$286
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,570 in reported general payments places this provider in the 55th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$120,787
Medicare patients
779
Services billed
2,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban623$752,349
EntrestoSacubitril/Valsartan215$311,004
XareltoRivaroxaban168$209,960
JardianceEmpagliflozin183$203,305
FarxigaDapagliflozin Propanediol127$163,597
Repatha SureclickEvolocumab129$111,824
MultaqDronedarone Hcl24$52,292
Praluent PenAlirocumab35$19,856
BrilintaTicagrelor14$12,057
Repatha SyringeEvolocumab14$11,588
Metoprolol Succinate559$9,077
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,611
Atorvastatin Calcium386$6,178
Icosapent Ethyl12$5,986
Diltiazem 24hr Er (Cd)Diltiazem Hcl155$5,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$376$752,349623 claims
NovartisEntresto$971$311,004215 claims
Johnson & JohnsonXarelto$304$209,960168 claims
Boehringer IngelheimJardiance$324$203,305183 claims
AstraZenecaFarxiga, Brilinta$217$175,654141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →